- Aug 18, 2021
- 1 min read

SynaptixBio Formed to Tackle One of the World’s Rarest Diseases

Updated: Dec 16, 2021

SynaptixBio CEO and Co-Founder Dan Williams/Courtesy SynaptixBio

TUBB4a-related leukodystrophy is considered one of the rarest diseases in the world. There is no cure. But its presumed rarity hasn’t stopped a group of scientists in Oxford, UK from forming a company to treat its underlying causes.

“We’re hoping to stabilize the disease by tackling it at its source, which could lead to the extension of patients’ lives,” Dan Williams, Ph.D., CEO and co-founder of SynaptixBio, told BioSpace.

To continue reading please go to the article on BioSpace.

Recent Posts

See All

TUBB4A-associated leukodystrophy

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr

Business digest C&I Issue 11, 2021

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst

New biotech firm launched to develop ‘revolutionary’ treatment for one of world’s rarest diseases

A new biotech business SynaptixBio has been launched to tackle one of the world’s rarest neurodegenerative diseases. SynaptixBio is working to develop the world’s first disease-modifying treatment for